奥司他韦与儿童流感相关并发症:基层医疗回顾性队列研究
倾向评分分析显示奥司他韦与流感相关并发症减少相关(RD -0.015,95%CI -0.022~-0.008),工具变量分析亦显示减少(RD -0.032,95%CI -0.051~-0.013)。结论认为奥司他韦对大流行期间儿童流感相关并发症有小幅但统计学显著的减少。
要点
- 倾向评分法显示奥司他韦减少流感相关并发症(RD -0.015)。
- 工具变量法显示奥司他韦减少流感相关并发症(RD -0.032)。
核心结论
- 基于观察性数据的因果推断分析,奥司他韦治疗与大流行期间儿童流感/流感样疾病的流感相关并发症小幅但统计学显著的减少相关。
研究设计与样本
- 采用双重稳健逆概率加权倾向评分法和医生既往处方工具变量法估计奥司他韦的因果效应。
主要发现
- 倾向评分分析:奥司他韦与流感相关并发症减少相关(RD -0.015,95%CI -0.022~-0.008),并与需进一步干预的并发症、肺炎、肺炎或住院、流感相关住院相关,但与全因住院无关。
- 调整后工具变量分析:奥司他韦与流感相关并发症减少相关(RD -0.032,95%CI -0.051~-0.013),并与肺炎或住院、全因住院及流感相关住院相关。
关键数值与推荐
- 原文未涉及诊断标准、治疗剂量或推荐条款的具体数值。
临床怎么用
- 在大流行期间,对基层就诊的流感/流感样患儿处方奥司他韦可能小幅降低流感相关并发症风险。
- 该证据来自观察性数据的因果推断,临床决策需结合患儿个体情况。
局限性
- 原文未明确列出局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Influenza and influenza-like illness (ILI) place considerable burden on healthcare systems, especially during influenza epidemics and pandemics. During the 2009/10 H1N1 influenza pandemic, UK national guidelines recommended antiviral medications for patients presenting within 72 h of ILI onset. However, it is not clear whether antiviral treatment was associated with reductions in influenza-related complications. METHODS: Our study population consisted of a retrospective cohort of children aged ≤17 years who presented with influenza/ILI at UK primary care practices contributing to the Clinical Practice Research Datalink during the 2009/10 pandemic. We used doubly robust inverse-probability weighted propensity scores and physician prior prescribing instrumental variable methods to estimate the causal effect of oseltamivir prescribing on influenza-related complications. Secondary outcomes were complications requiring intervention, pneumonia, pneumonia or hospitalisation, influenza-related hospitalisation and all-cause hospitalisation. RESULTS: We included 16 162 children, of whom 4028 (24.9%) were prescribed oseltamivir, and 753 (4.7%) had recorded complications. Under propensity score analyses oseltamivir prescriptions were associated with reduced influenza-related complications (risk difference (RD) -0.015, 95% CI -0.022--0.008), complications requiring further intervention, pneumonia, pneumonia or hospitalisation and influenza-related hospitalisation, but not all-cause hospitalisation. Adjusted instrumental variable analyses estimated reduced influenza-related complications (RD -0.032, 95% CI -0.051--0.013), pneumonia or hospitalisation, all-cause and influenza-related hospitalisations. CONCLUSIONS: Based on causal inference analyses of observational data, oseltamivir treatment in children with influenza/ILI was associated with a small but statistically significant reduction in influenza-related complications during an influenza pandemic.
引用
- Lee JJ, Smith M, Bankhead C, et al. Oseltamivir and influenza-related complications in children: a retrospective cohort in primary care. Eur Respir J. 2020. PMID: 32527739. doi:10.1183/13993003.02246-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。